Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict

Group 1 - Biohaven Ltd. (NYSE: BHVN) is a clinical-stage biopharmaceutical company focused on developing treatments for neurological, immunological, oncological, and metabolic conditions [1] - The company's lead asset, Troriluzole, is currently facing regulatory uncertainty in Europe and is awaiting a significant FDA decision in the US [1] - Recently, Biohaven raised $600 million, indicating a strong financial position to support its ongoing development efforts [1]